CAJ | 학술논문

目的：观察紫杉醇联合替吉奥胶囊治疗晚期食管癌的临床疗效和不良反应。方法选择37例晚期食管癌患者，予紫杉醇175 mg/m2， d1，静脉滴注3 h；替吉奥胶囊服用剂量按体表面积＜1.25 m2者剂量40毫克/次；体表面积1.25～1.5 m2者剂量50毫克/次；体表面积＞1.5 m2者剂量60毫克/次；均每日2次，早晚餐后口服，连服14 d，21 d为1个周期。结果疗效可评价患者36例，其中完全缓解（CR）1例，部分缓解（PR）14例，病情稳定（SD）11例，病情进展（PD）10例，有效率（CR+PR）为41.7%；疾病控制率（CR+PR+SD）为72.2%；中位疾病进展时间（mTTP）及中位生存时间分别为7.4个月、10.6个月，1年生存率为36.1%。化疗的主要不良反应为脱发及骨髓抑制，其中Ⅲ～Ⅳ度中性粒细胞减少发生率为16.7%。结论紫杉醇联合替吉奥胶囊治疗晚期食管癌疗效肯定，且耐受性较好。
목적：관찰자삼순연합체길오효낭치료만기식관암적림상료효화불량반응。방법선택37례만기식관암환자，여자삼순175 mg/m2， d1，정맥적주3 h；체길오효낭복용제량안체표면적＜1.25 m2자제량40호극/차；체표면적1.25～1.5 m2자제량50호극/차；체표면적＞1.5 m2자제량60호극/차；균매일2차，조만찬후구복，련복14 d，21 d위1개주기。결과료효가평개환자36례，기중완전완해（CR）1례，부분완해（PR）14례，병정은정（SD）11례，병정진전（PD）10례，유효솔（CR+PR）위41.7%；질병공제솔（CR+PR+SD）위72.2%；중위질병진전시간（mTTP）급중위생존시간분별위7.4개월、10.6개월，1년생존솔위36.1%。화료적주요불량반응위탈발급골수억제，기중Ⅲ～Ⅳ도중성립세포감소발생솔위16.7%。결론자삼순연합체길오효낭치료만기식관암료효긍정，차내수성교호。
Objective To observe the clinical effect and Side-effect of paclitaxel combined with S-1 capsule for elderly advanced esophageal cancer. Methods Thirty-seven patients with elderly advanced esophageal cancer were treated with paclitaxel and S-1 capsule. Patients were given paclitaxel 175 mg/m2 by 3-hours infusion on D1, and S-1 capsule(according to body surface area,<1.25 m2 40 mg;1.25~1.5 m2 50 mg;>1.5 m2 60 mg)orally, twice daily for 14 days.The chemotherapy was repeated every 21 days. Results One case showed complete remission (CR), 14 cases partial remission(PR), 11 cases stable disease(SD),10 cases progressive disease(PD). Response rate(CR+PR)was 41.7%;Illness control rate(CR+PR+SD)was 72.2%;The median time to tumor progression and the median actuarial survival were respectively 7.4 months and 10.6 months;The 1-year survival rate was 36.1%. The most common Side-effect was alopecia. Grade 3 to 4 neutropenia was observed in 16.7%. Conclusion Paclitaxel combined with S-1 capsule is effective and tolerable in treatment of patients with elderly advanced esophageal cancer.